Myriad Genetics diskutieren
Myriad Genetics
WKN: 897518 / Symbol: MYGN / Name: Myriad Genetics / Aktie / Ausrüstung & Versorgung / Mid Cap /
?
-4,10 %
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at Raymond James from $25.00 to $27.00. They now have an "outperform" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "sell" rating to a "buy" rating. They now have a $25.00 price target on the stock, up previously from $18.00.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $25.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have an "underweight" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $17.00 to $14.00. They now have an "underweight" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $28.00 price target on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $23.00 price target on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $35.00 price target on the stock, up previously from $25.00.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "underperform" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $20.00 price target on the stock, down previously from $25.00.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $20.00. They now have an "underweight" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Bank of America Co. from $15.00 to $13.00. They now have an "underperform" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $29.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $29.00 price target on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $19.00 price target on the stock, down previously from $27.00.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Bank of America Co. from $13.00 to $11.00. They now have an "underperform" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $18.00 to $14.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $10.00 price target on the stock, down previously from $19.00.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $14.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $12.50 to $9.00. They now have an "overweight" rating on the stock.
Ratings data for MYGN provided by MarketBeat
Neueste Beiträge
Stifel_Nicolaus in C.H. Robinson Worldwide Inc. diskutieren